Physicians' Academy for Cardiovascular Education

Proof-of-Concept Studie: Zusätzliche therapeutische Strategie neben der Lipidsenkung reduziert das kardiovaskuläre Risiko

Sep. 29, 2017 - ESC 2017, Barcelona, Spain

Inflammation Expert Opinions Prof. Wolfgang Koenig: Die CANTOS Studie belegt dass inflammatorische Prozesse eine kausale Rolle in der Atherogenese spielen. Inhibition der Inflammation führt zu einer weiteren Reduktion des kardiovaskulären Risikos ohne Beeinflussung des Lipidstatus.

Educational information

The CANTOS trial is the first in a series of trials that test the hypothesis that inhibiting inflammation can lower residual CV risk. The results of this trial indeed confirm this hypothesis, suggesting that from now on, targeting inflammation may need to be considered in patients on lipid-lowering therapy with residual inflammatory CV risk.

These inflammation expert opinion videos are aimed to provide guidance and perspectives on the implications of the CANTOS trial and other trials addressing inflammation in CVD. These expert views may help translate scientific findings to future clinical practice, by improving personalized CV risk management.

This recording was developed under auspices of PACE-cme.

The views expressed in this recording are those of the presenter and do not necessarily reflect the views of PACE-cme.

Disclosures

Wolfgang Koenig, MD, PhD, FRCP, FACC, FAHA, FESC is a Professor of Medicine/Cardiology at the University of Ulm Medical School, Ulm, Germany.

Funding

Funding to produce this video was provided by an unrestricted educational grant from Novartis.